Vir Biotechnology, Inc.
VIR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.12 | 0.05 | -0.02 |
| FCF Yield | -17.59% | -8.95% | -8.97% | -16.98% |
| EV / EBITDA | -4.15 | -5.22 | -7.71 | -4.49 |
| Quality | ||||
| ROIC | -10.87% | -11.84% | -9.10% | -15.62% |
| Gross Margin | 99.09% | 100.00% | 93.94% | 97.90% |
| Cash Conversion Ratio | 1.03 | 1.08 | 0.65 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.84% | -66.17% | -63.98% | -64.19% |
| Free Cash Flow Growth | -53.94% | 11.44% | 48.20% | -121.41% |
| Safety | ||||
| Net Debt / EBITDA | 1.74 | 1.30 | 1.10 | 0.26 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -100,096.36 | 0.00 | -627.85 | -12,948.58 |